Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet Oncol · 2026-10-25

Phase 3 trial, 231 patients with locally advanced rectal cancer: short-course radiotherapy, camrelizumab and CAPOX vs long-course chemoradiotherapy then CAPOX. Primary pCR 39.8% vs 15.3%; interim 3-year event-free survival 91.3% vs 77.4% (HR 0.33).

RCTn = 231
Tao et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
Oncology · Lancet Oncol · 2026-10-01

Prespecified 10-year analysis of 810 women with high-risk breast cancer after mastectomy: locoregional recurrence was 12.0% with hypofractionated (43.5 Gy/15) vs 10.3% with conventional (50 Gy/25) radiotherapy (HR 1.19, 0.79-1.82); grade 3 late toxicity was rare in both.

RCTn = 810
Sun et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial
Oncology · J Clin Oncol · 2026-09-09

Secondary analysis of a phase II trial of preoperative radiotherapy with or without pembrolizumab in 106 patients with localised soft tissue sarcoma: personalised ctDNA was found in 85% at baseline and levels independently predicted survival.

Secondary analysisn = 106
Subramanian et al. Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial
Oncology · Lancet · 2026-09-06

In patients with high-risk, inoperable early-stage NSCLC, adding atezolizumab to SBRT did not improve overall survival vs SBRT alone (HR 1.04; 2-year OS 82% in both groups). The trial closed for futility. Grade ≥3 adverse events were 12% vs 3%.

RCTn = 417
Daly et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
Oncology · Lancet Oncol · 2026-08-23

In early and intermediate-stage rectal cancer patients choosing organ preservation, 12-month TME-free survival was 78.5% with long-course chemoradiotherapy vs 60.6% with short-course radiotherapy (HR 1.90) in an early analysis; the 30-month primary endpoint is awaited.

RCTn = 409
Bach et al. Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.